胃がん治療におけるATR-CHK1軸阻害剤
Mateusz Kciuk1, Renata Gruszka1, Marta Aleksandrowicz2
1Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland.
International journal of molecular sciences
|August 28, 2025
まとめ
ATR-CHK1阻害剤は,DNA損傷反応経路を標的として,胃がんの治療に有望であることが示されています. このアプローチは,特に他の治療法と組み合わせると,病気が進行した患者に新しい治療戦略を提供します.
科学分野:
- 腫瘍学
- 分子生物学
- ガン治療薬
背景:
- 胃がんは,先進的な症例の予後が悪いことで,世界的な健康負担を大きくします.
- 腫瘍は,頻繁なTP53変異,ARID1A喪失,ATM欠陥,複製ストレスを含むDNA損傷反応 (DDR) 経路の脆弱性を表しています.
- これらの脆弱性により,ATR-CHK1軸が癌細胞の生存に左右されます.
研究 の 目的:
- 胃がんの治療におけるATRおよびCHK1阻害剤に関する現在の臨床および臨床前研究の証拠をレビューする.
- 合成の致死性と免疫調節に基づくこれらの阻害剤の可能性を調査する.
- 治療の失敗を克服するための抵抗メカニズムと戦略について議論する.
主な方法:
- ATR/ CHK1阻害剤に関する既存の臨床および臨床前データの統合.
- DDR経路に焦点を当てた胃がんの分子脆弱性の分析
- 化学療法,放射線療法,免疫療法を含む組み合わせ戦略のレビュー
主要な成果:
- ATR- CHK1軸の抑制は胃がんの有望な治療戦略です.
- 化学療法,放射線療法,または免疫チェックポイント阻害剤との併用療法は有効性を高める可能性があります.
- バイオマーカーによる選択と適応的な投与は,治療の精度を最適化し,毒性を減らすために不可欠です.
結論:
- ATR- CHK1阻害剤は,特定の胃がんのサブセットを治療するための合理的なアプローチを提供します.
- 効果的な治療戦略の開発には 抵抗メカニズムを理解することが重要です
- これらの阻害剤のさらなる研究と臨床統合は,バイオマーカーで定義された患者集団のために正当化されています.
関連する概念動画
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
DNA Damage can Stall the Cell Cycle
9.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K


